Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amakem, a Belgium-based developer of new treatments for serious eye conditions, has received EUR18m fund to enhance its ophthalmology drug development program.
Subscribe to our email newsletter
The funding has been awarded by its existing investors along with Forbion Capital Partners, Credit Agricole Private Equity and Vesalius BioCapital.
The company has progressed its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.
In the preclinical studies, AMA0076 showed reduction in intraocular pressure (IOP).